European Statistical Meeting Oncology and Survival Analysis

09:30-17:00 Friday 17th November 2017 BMS, Brussels

Survival analysis methods, or 'Time to event' methods, are used in many clinical indications for the development, regulatory approval, and health technology assessment of new therapeutics. Originally developed to analyse trial endpoints in oncology, they are now used in many other indications. This meeting aims to bring together statisticians from the pharmaceutical industry, academia and regulatory agencies to hear about recent advances in survival analysis methods and their application in oncology.

Confirmed speakers include

Michal Kicinsky and Nathan Touati EORTC

Statistical challenges in immunotherapy

trials: EORTC's views

Everardo Saad

IDDI

Surrogate endpoints in oncology: objectives, methodological overview,

and current status

Federico Rotolo CESP INSERM Multimarker-based subgroups in time-to-

event randomized clinical trials

Gerd Rosenkranz Medical University of

Vienna

Subgroup Identification via the Predicted

Individual Treatment Effect

Steven Teerenstra

Radboud University Nijmegen Medical Center and MEB Estimands in Oncology

Julien Péron Lyon University Generalized Pairwise Comparison on Immuno-Oncology clinical trial data: a

case study"

Agnes Balogh

BMS

Multiplicity Correction in a Group-

Sequential Oncology Trial Including Subgroup Analyses and Multiple Primary

Endpoints: a Case Study

The program will also include a panel discussion with the speakers and **Bertil Jonsson** (Medical Products Agency and EMA)



Venue

NV Bristol-Myers Squibb Belgium SA Parc de l'Alliance Avenue de Finlande 4 B – 1420 Braine-l'Alleud Belgium

Registration

Fee includes lunch & refreshments

On or before October 17th

Industry rate: €170.00 Academic rate: €110.00

After October 17th

Industry rate: €200.00 Academic rate: €130.00

To attend this meeting register your details at:

www.efspi.org

or contact

EFSPI Secretariat

Tel: +44 (0) 1625 664549 efspi@kingstonsmith.co.uk

For information regarding the scientific content contact:

emmanuel.quinaux@iddi.com or francois.aubin@venncro.com